Nicole Wandrey, Luke Hamilton, Jake Boley, Alexis Haynes, Makenna Redinger, Mackinzi Hill, Mackenzie Hagemeister, Philip A Cole, Michael A Moxley, Allen A Thomas
Bioorganic & medicinal chemistry letters 2024 Nov 15Arylalkylamine N-acetyltransferase (AANAT) catalyzes the rate-limiting step in melatonin synthesis and is a potential target for disorders involving melatonin overproduction, such as seasonal affective disorder. Previously described AANAT inhibitor bromoacetyltryptamine (BAT) and benzothiophenes analogs were reported to react with CoASH to form potent bisubstrate inhibitors through AANAT's alkyltransferase function, which is secondary to its role as an acetyltransferase. We replaced the bromoacetyl group in BAT with various Michael acceptors to mitigate possible off-target activity of its bromoacetyl group. Additionally, we modified the length of the carbon linker between the Michael acceptor and indole bicycle of tryptamine to determine its effect on potency. An AANAT enzymatic assay showed a two-carbon linker present in BAT was optimal, while none of the new warheads had activity. Kinetic analysis indicated that these Michael acceptors reacted with CoASH much slower than BAT and not within the timeframe of our enzymatic assay. Additionally, we confirmed earlier reports that the acetyltransferase function of AANAT follows an ordered bi bi mechanism in which AcCoA binds before serotonin. In contrast, BAT's alkyltransferase kinetics revealed a bi uni mechanism in which BAT binds to AANAT before CoASH. Our model combines both functions of AANAT into one kinetic mechanism. Copyright © 2024 Elsevier Ltd. All rights reserved.
Nicole Wandrey, Luke Hamilton, Jake Boley, Alexis Haynes, Makenna Redinger, Mackinzi Hill, Mackenzie Hagemeister, Philip A Cole, Michael A Moxley, Allen A Thomas. AANAT kinetics of CoASH-targeted electrophiles of tryptamine and related analogs. Bioorganic & medicinal chemistry letters. 2024 Nov 15;113:129975
PMID: 39332648
View Full Text